Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The Tokyo-based drug company Eisai has agreed to pay $325 million for Morphotek, an Exton, Pa., developer of monoclonal antibody therapeutics. The deal expands Eisai's oncology drug discovery efforts beyond small molecules. In addition to Morphotek's human antibody technology platform, Eisai gains an antibody in Phase I/II trials for ovarian cancer, another drug in Phase I trials for pancreatic cancer, and a range of antibodies in preclinical studies.
This article has been sent to the following recipient: